What is the current market price of capmatinib in 2026?

Capmatinib (Capmatinib) is a targeted therapy drug specifically used to treat non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations. Its market price will be affected by original drugs, generic drugs and regional differences, so there are certain differences in pricing in different regions.

In China, the original drug of capmatinib has been approved for marketing and has been included in medical insurance. Patients can enjoy certain reimbursement discounts within the scope of medical insurance. Common capmatinib specifications include200mg 60 tablets and 150mg 60 tablets. Depending on the specifications and manufacturers, the selling price of capmatinib in the domestic market is approximately RMB 30,000 (the specific price may fluctuate due to regional differences). The launch of capmatinib provides a new treatment option for patients with non-small cell lung cancer suffering from MET exon 14 skipping mutations, and can reduce the cost of treatment for patients within the scope of medical insurance.

In overseas markets, the price of capmatinib’s original drug is usually higher, especially in the European market. The price of the European version of capmatinib (200mg*60 tablets) is approximately more than 50,000 yuan, and the price may fluctuate due to exchange rates. Compared with original drugs, there are also some generic drugs available in overseas markets. The ingredients of these generic drugs are basically the same as the original drugs and the prices are relatively low.

For example, the price of generic capmatinib (200mg*56 tablets) produced by a pharmaceutical factory in Laos in overseas markets is more than 2,000 yuan. Compared with brand-name drugs, these generic drugs provide more cost-effective options, especially suitable for some patients who do not have medical insurance coverage. However, when choosing generic drugs, patients should ensure that the purchase channels are formal to ensure the quality and efficacy of the drugs.

In short, the price of capmatinib will be affected by drug policies, manufacturers and exchange rate fluctuations in different regions. Patients need to consult doctors and pharmacists when purchasing to choose the treatment plan that best suits them.

Keyword tags: capmatinib,Capmatinib, MET gene mutation, non-small cell lung cancer, targeted therapy, original drug, generic drug, drug price, medical insurance reimbursement

Reference materials:https://go.drugbank.com/drugs/DB11791